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Abstract
Chronic wasting disease (CWD) is a contagious, rapidly spreading transmissible spongiform encephalopathy (TSE), or prion
disease, occurring in cervids such as white tailed-deer (WTD), mule deer or elk in North America. Despite efficient horizontal
transmission of CWD among cervids natural transmission of the disease to other species has not yet been observed. Here,
we report for the first time a direct biochemical demonstration of pathological prion protein PrP
TSE and of PrP
TSE-associated
seeding activity, the static and dynamic biochemical markers for biological prion infectivity, respectively, in skeletal muscles
of CWD-infected cervids, i. e. WTD for which no clinical signs of CWD had been recognized. The presence of PrP
TSE was
detected by Western- and postfixed frozen tissue blotting, while the seeding activity of PrP
TSE was revealed by protein
misfolding cyclic amplification (PMCA). Semi-quantitative Western blotting indicated that the concentration of PrP
TSE in
skeletal muscles of CWD-infected WTD was approximately 2000-10000 -fold lower than in brain tissue. Tissue-blot-analyses
revealed that PrP
TSE was located in muscle-associated nerve fascicles but not, in detectable amounts, in myocytes. The
presence and seeding activity of PrP
TSE in skeletal muscle from CWD-infected cervids suggests prevention of such tissue in
the human diet as a precautionary measure for food safety, pending on further clarification of whether CWD may be
transmissible to humans.
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Introduction
Prions, proteinaceous infectious particles, are the causative
agents of transmissible spongiform encephalopathies (TSEs) [1,2],
fatal neurodegenerative disorders of the central nervous system
(CNS) such as scrapie in sheep and goats, bovine spongiform
encephalopathy (BSE) in cattle, chronic wasting disease (CWD) in
cervids or Creutzfeldt-Jacob disease (CJD) and its variant form
(vCJD) in humans [3].
Prions are thought to consist essentially – if not entirely – of
host-encoded prion protein (PrP) with a pathological folding and
aggregation structure, referred to as PrP
Sc or PrP
TSE [2,4].
Substantial evidence suggests that the replication of prions is
mediated by a process of seeded polymerization [5]. In this process
PrP
TSE particles (that may or may not contain further components
or obtain assistance by helper molecules) exert a proteinaceous
seeding activity by putatively acting as nuclei which recruit cellular
prion protein (PrP
C) and incorporate it, in a beta-sheet rich
amyloid form, into growing aggregates of misfolded PrP.
Fragmentation of aggregates with a critical size eventually
mediates the multiplication of particles with proteinaceous seeding
activity, resulting in autocatalytic replication of the pathological
protein state. PrP
TSE has been empirically established as a static
biochemical infectivity marker for several different TSE agents
under defined analytical conditions, while prion replication by
seeded polymerization would conceptually implicate the seeding
activity of PrP
TSE as the dynamic biochemical correlate to
biological prion infectivity [6,7]. Protein misfolding cyclic
amplification (PMCA), which models seeded polymerization of
PrP in vitro has been established during the past few years as a
powerful tool for the ultra-sensitive detection of minute amounts of
PrP
TSE and PrP
TSE-associated seeding activity [8,9].
In individuals with experimentally induced or naturally
acquired TSEs prion infectivity and PrP
TSE predominantly
accumulate in the CNS but were also found, to varying degrees,
in peripheral tissues [2,10–12]. Together with CJD and scrapie
CWD is one of three naturally occurring forms of prion disease
[13]. CWD is contagious and has shown an increasing spread
during the past few years in captive as well as free ranging cervids
in North America [14]. This has raised concerns for risks of
zoonotic CWD transmission to humans via foodstuffs from cervids
– not least because the question of whether CWD prions have the
ability to infect humans has not yet been definitely resolved.
Skeletal muscles from farm- and game animals provide a frequent
component of the human diet, and muscle tissue from scrapie-
infected mice, hamsters and sheep, or from humans with classical
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infectivity and/or PrP
TSE [10,11,15–17]. In 2006, Angers et al.
[18] reported the detection of prion infectivity in specimens of
skeletal muscle from CWD-affected mule deer by bioassay.
Although such muscle samples induced disease in reporter
animals, PrP
TSE or its proteinaceous seeding activity could not
be detected directly in skeletal muscles of CWD-infected cervids so
far [19–21].
Therefore, we applied a high-yield method for the extraction of
PrP
TSE from muscle samples of CWD-infected WTD and
screened the extracts from different skeletal muscles by highly
sensitive Western blotting for the presence of PrP
TSE. In addition
to farmed WTD culled in Saskatchewan, Canada, we also
analyzed hunter-killed game WTD from Wisconsin, USA. All
farmed and free-ranging WTD examined in our study (except for
the donor animal of negative control samples) had been officially
diagnosed positive for CWD infection by the responsible
authorities based on an analysis of brain and/or lymphatic tissue
for the presence of PrP
TSE, although no clinical signs of CWD had
been recognized in these animals. In our study, we detected, for
the first time, PrP
TSE and PrP
TSE-associated seeding activity in
skeletal muscles of farmed and free-ranging cervids infected with
CWD. Tissue-blotting revealed that PrP
TSE was located in muscle-
associated nerve fascicles while PrP
TSE was not detectable in
mycoytes.
Results
Detection and semi-quantitative assessment of PrP
TSE in
skeletal muscles of CWD-infected white-tailed deer by
Western blotting
As evidenced by semi-quantitative Western blotting CWD-
associated PrP
TSE could be recovered, using our extraction
procedure, with a yield of approximately 20% from cervid muscle
tissue that had been spiked with CWD brain homogenate from
WTD in the clinical stage of disease (figure 1).
By using this procedure for the extraction of PrP
TSE 13 skeletal
muscle samples taken from WTD previously found to be infected
with CWD were tested for the presence of PrP
TSE (table 1). Three
out of four donor animals were positive for pathological prion
protein PrP
TSE in the M. semimembranosus/tendinosus, whereas three
out of nine animals showed PrP
TSE in M. glutaeobiceps in the
Western blot. This may be indicative of a more pronounced
accumulation of PrP
TSE in the M. semimembranosus/tendinosus as
compared to the M. glutaeobiceps. However, it has to be noted that
the stage of CWD progression was unknown, and possibly differed,
for the examined muscle donors. Selected Western blot findings
from our study are shown in figure 2. Positive results for farmed
cervids are displayed in lanes 4 and 5, while PrP
TSE detection in
muscle specimens from hunter-kill animals is shown in lanes 6 and
7. Although the donor animal of the muscle sample blotted in lane
8 was previously found to be positive for PrP
TSE in brain tissue,
too, no PrP
TSE could be detected in the examined muscle sample.
Negative control muscle from uninfected WTD did not show any
PrP
TSE staining in independently repeated analyses as exemplified
in lane 9.
Staining intensities for PrP27-30, the Proteinase K-resistant core
of PrP
TSE, in extracts from test samples representing 100 mg each
of muscle tissue from CWD-infected WTD were approximately in
the range of signal intensities produced by reference samples
containing 10–50 mg of CWD brain tissue from a WTD in the
clinical stage of disease (figure 2, lanes 4–7 vs. lanes 2&3).
However, the amount of PrP
TSE in tested samples varied for
different skeletal muscles and animals. A semi-quantitative
assessment based on the Western blot findings shown in figure 2
would suggest an about 2000–10000- fold lower concentration of
PrP
TSE in the tested muscle tissues as compared to CWD brain
tissue.
Proteinaceous seeding activity of muscle-associated
PrP
TSE
The presence of PrP
TSE evidenced by Western blotting
suggested a contamination of muscle specimens with infectious
CWD prions. This prompted us to further examine selected
muscle samples for the presence of PrP
TSE-associated seeding
activity, the putative dynamic biochemical correlate of biological
prion infectivity (table 1).
By applying a PMCA protocol that used normal hamster brain
homogenate as substrate for the in vitro amplification of Proteinase
K-resistant prion protein (PrPres) muscle extracts from CWD-
infected cervids were examined for their seeding activity on PrP
C.
CWD-associated PrP
TSE from the brain of infected WTD was
found to effectively seed conversion of PrP in normal hamster
brain homogenate as shown by PMCA findings such as displayed
in figure 3A. Proteinaceous seeding activity was also observed in
PrP
TSE-extracts from muscles of CWD-infected cervids as shown
in figure 3B for an extract from M. semimembranosus/tendinosus (same
sample as blotted in lane 5 of figure 2; Fa-WTD 1).
Figure 3 C displays the result of a PMCA run seeded with a
muscle PrP
TSE-extract for which a direct detection of PrP
TSE was
not possible by Western blotting (same sample as shown in figure 2,
lane 8; Fa-WTD 2). A weak PrPres signal occurred after 7 rounds
of PMCA (it has to be noted that this muscle extract was prepared
from an animal that had been previously found positive for PrP
TSE
in the brain). The negative PMCA control (figure 3D) did not
produce any detectable PrPres amplification.
Intramuscular location of PrP
TSE
The location of PrP
TSE in muscle tissue was examined by tissue
blotting (and supplementary H&E staining for histomorphological
orientation) of sample sections (table 1).
Tissue-blotting exclusively revealed deposition of PrP
TSE in
nerve fascicles while no PrP
TSE could be visualized in muscle fibres
(i.e. myocytes) from CWD-infected WTD (figure 4A & B; FR-
WTD 2). No immunostaining was detectable in tissue blots of
muscle tissue from uninfected WTD (figure 4C & D; Fa-WTD 10).
Figure 1. Recovery of PrP
TSE after extraction from muscle
tissue. Western blot detection of PrP27-30, the Proteinase K-resistant
core of PrP
TSE, after labelling with anti-PrP monoclonal antibody ICSM-
18. Lanes 1–4; Proteinase K-digested brain homogenates from WTD in
the clinical stage of CWD representing 5610
25 g (lane 1), 1610
25 g
(lane 2), 5610
26 g (lane 3) and 1610
26 g (lane 4) of CWD brain tissue.
Lane 5; PrP
TSE extract from 100 mg of skeletal muscle (M. glutaeobiceps)
from an uninfected control WTD (blotted also in lane 9 of figure 2; Fa-
WTD 10) spiked before extraction with 1610
25 g of CWD brain tissue
from a WTD in the clinical stage of disease.
doi:10.1371/journal.pone.0018345.g001
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In the wake of the BSE epidemic, variant Creutzfeldt-Jakob
disease has emerged as a previously unknown prion disease of
humans. This has shown that significant risks for public health
may potentially emanate from the presence of animal prions in
human foodstuffs. When assessing such risks in the context of
CWD, key factors that need to be considered are i) the distribution
of CWD prions in infected animals and ii) the potential
transmissibility of such prions to humans.
PMCA-based in vitro studies have indicated a rather high
transmission barrier for CWD to macaques as well as to transgenic
mice expressing the human prion protein, as no conversion of
cellular prion proteins into PrPres could be induced by seeding
PMCA reactions with CWD-infected brain tissue [22]. Consistent
with these findings, transgenic mice overexpressing human prion
protein with methionine or valine at polymorphic residue 129
were resistant to infection with CWD prions from mule deer [23].
Furthermore, recent in vivo studies revealed a robust barrier for the
transmission of CWD to macaques which, again, is suggestive of a
rather low risk for CWD transmission to humans [24]. However,
squirrel monkeys could be infected with CWD [24], and
increasing evidence points to the existence of different CWD
isolates [25,26]. Thus, it remains to be further clarified whether
CWD may be caused by multiple prion strains with distinct
transmission properties.
It has been shown previously that skeletal muscle tissue from
CWD infected mule deer may contain prion infectivity [18]. Also,
Western blot- and immunohistochemical analyses of heart muscles
from CWD-infected Rocky mountain elk and white-tailed deer
revealed the presence of pathological prion protein in cardiac
myocytes. PrP
TSE was found in the left ventricle of the heart at a
10- to 100- fold lower concentration as compared to the brain, but
not in skeletal muscle [27].
Here we report the direct detection of pathological prion
protein PrP
TSE and of PrP
TSE-associated seeding activity in
skeletal muscles from cervids, i. e. WTD for which no clinical
signs of prion disease had been recognized, using Western blotting,
tissue blotting and PMCA as analytical techniques. Kurt et al. [22]
recently reported that normal brain homogenate (NBH) from
Syrian hamsters effectively supports the amplification of PrPres
from CWD seeds in serial PMCA. Building on similar findings
previously made in our laboratory (not shown) we also used
hamster NBH as substrate for our PMCA analyses. We found that
PrPres generated by PMCA after seeding with CWD- or 263K
scrapie agents did not exhibit significant differences in the
glycosylation- or electrophoretic migration patterns (not shown).
As a safeguard to PMCA specificity safety measures aimed at
preventing inadvertent cross-contamination with both prions from
cervids or hamsters were implemented. Specifically, we sealed our
PMCA reaction tubes with parafilm and paraffin wax, performed
all pipetting steps exclusively with plugged single-use pipette tips,
Table 1. Presence and seeding actvity of PrP
TSE in skeletal muscles from CWD-infected white-tailed deer.
Donor animal Clinical symptoms
Official test for CWD
infection{ Analysis of M. semimembranosus/M. tendinosus
Analysis of M.
glutaeobiceps
WB SA WB TB
FR-WTD 1 2 + + n.e. n.a. n.a.
FR-WTD 2 2 + + n.e. + +
Fa-WTD 1 2 + + +++ 2 n.e.
Fa-WTD 2 2 + 2 + n.a. n.a.
Fa-WTD 3 2 + n.a. n.a. 2 n.e.
Fa-WTD 4 2 + n.a. n.a. 2 n.e.
Fa-WTD 5 2 + n.a. n.a. 2 n.e.
Fa-WTD 6 2 + n.a. n.a. 2 n.e.
Fa-WTD 7 2 + n.a. n.a. 2 n.e.
Fa-WTD 8 2 + n.a. n.a. + n.e.
Fa-WTD 9 2 + n.a. n.a. + n.e.
Fa-WTD 10 22 n.a. n.a. 22
Footnote to Table 1. Explanation of abbreviations: n.a. – no tissue available for testing; n.e. – not examined; SA – PMCA testing for seeding activity of PrP
TSE;T B–
Tissue blot testing for PrP
TSE; WB – Western blot testing for PrP
TSE. Explanation of symbols:
{Western blot testing of WTD brain tissue and/or lymph nodes for PrP
TSE was performed by the responsible authorities in Canada or the USA in the context of CWD
surveillance.
doi:10.1371/journal.pone.0018345.t001
Figure 2. Detection and semi-quantitative assessment of PrP
TSE
in skeletal muscles of CWD-infected WTD. Western blot detection
of PrP27-30, the Proteinase K-resistant core of PrP
TSE, after labelling with
anti-PrP monoclonal antibody ICSM-18. Lanes 1–3, PrP
TSE extracts from
100 mg of skeletal muscle from an uninfected control WTD (blotted
also in lane 9) spiked before extraction with 1610
24 g (lane 1),
5610
25 g (lane 2), and 1610
25 g of CWD brain tissue from a WTD in
the clinical stage of disease. Lanes 4–8, PrP
TSE extracts from 100 mg
samples of the following muscles from CWD-infected WTD: M.
glutaeobiceps (farmed animal Fa-WTD 8, lane 4), M. semimembranosus/
tendinosus (farmed animal Fa-WTD 1, lane 5), M. semimembranosus/
tendinosus (hunter-kill animal FR-WTD 1, lane 6), M. semimembranosus/
tendinosus (hunter-kill animal FR-WTD 2, lane 7), M. semimembranosus/
tendinosus (farmed animal Fa-WTD 2, lane 8). Lane 9, extract from
100 mg sample of M. glutaeobiceps from an uninfected control WTD
(Fa-WTD 10).
doi:10.1371/journal.pone.0018345.g002
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sample. With these safety measures in place unseeded controls in
which PMCA was performed with normal hamster brain
homogenate only did not produce any unspecific PrPres staining
in our experimental setup.
Our findings were obtained by an alternative methodology to
bioassays in animals (i. e. combined biochemical detection of
PrP
TSE and its proteinaceous seeding activity) but are consistent
with the observations reported by Angers et al. [18]. They may
also provide an explanation for the negative findings by Jewell
et al. [27] in skeletal muscle, since our Western blot results indicate
a substantially lower concentration of PrP
TSE in such tissue than
reported for heart muscle.
Yet, it has to be noted that our assessments of PrP
TSE levels in
skeletal muscles were based on findings in presumably pre- or
subclinically infected animals. Therefore, the concentration of
PrP
TSE in skeletal muscles of WTD with clinically manifest CWD
may possibly exceed our estimate which refers to clinically
inconspicuous animals that are more likely to enter the human
food chain. Our tissue blot findings in skeletal muscles from CWD-
infected WTD would be consistent with an anterograde spread of
CWD prions via motor nerve fibres to muscle tissue (figure 4A).
Similar neural spreading pathways of muscle infection were
previously found in hamsters orally challenged with scrapie [28]
and suggested by the detection of PrP
TSE in muscle fibres and
muscle-associated nerve fascicles of clinically-ill non-human
primates challenged with BSE prions [29]. Whether the absence
of detectable PrP
TSE in myofibers observed in our study is a
specific feature of CWD in WTD, or was due to a pre- or
subclinical stage of infection in the examined animals, remains to
be established. In any case, our observations support previous
findings suggesting the precautionary prevention of muscle tissue
from CWD-infected WTD in the human diet, and highlight the
need to comprehensively elucidate of whether CWD may be
transmissible to humans. While the understanding of TSEs in
cervids has made substantial progress during the past few years,
the assessment and management of risks possibly emanating from
prions in skeletal muscles of CWD-infected cervids requires further
research.
Materials and Methods
Ethics Statement
We did not perform experiments in living animals. However,
tissue samples removed post mortem from farmed or free-ranging
deer and from normal Syrian hamsters were used in our study. All
animal work performed in this context was conducted in
accordance with relevant national and international guidelines.
The farmed or free-ranging deer from which muscle specimens for
our analyses were sampled had been culled in the context of
livestock farming or deer hunting in Saskatchewan, Canada or
Wisconsin, USA. Thus, the removal of tissue samples from these
cervids did not require specific approval by animal protection
institutions or ethic committees as required for experiments in
animals. The sacrifice of normal Syrian hamsters at the Robert
Koch-Institut (Berlin, Germany) for the removal of brain tissue to
be used in PMCA did not require approval by animal protection
instituitions or ethic committees, neither, according to German
regulations. However, euthanasia of hamsters for the preparation
of PMCA substrate was reported to and registered by the
responsible authority (Landesamt fu ¨r Gesundheit Berlin, Berlin,
Germany; http://www.lageso.berlin.de; registration number
T0220/07, dated 09 July 2008). Brain tissue from WTD in the
clinical stage of CWD used as reference material for Western
blotting and PMCA had been sampled in the course of a study
previously published by others [30].
Animal tissues
Specimens from skeletal muscles (M. semimembranosus/M.
tendinosus; M. glutaeobiceps) to be examined by Western blotting or
PMCA were taken from farmed or game WTD (Odocoileus
virginianus) culled in Saskatchewan, Canada (Fa-WTD 1–10) or
Wisconsin, USA (FR-WTD 1 & 2), respectively. M. glutaeobiceps for
tissue blotting was dissected from hunter-harvested animal FR-
WTD 2.
At necropsy, WTD torsos with attached extremities were
dissected separately from cervid heads. Dedicated sets of
instruments were used for the preparation of muscle samples
from hind limbs, and there was no contact of instruments or
dissected muscle specimens with extra-muscular tissues of the
carcass. All muscle tissues tested in our study were prepared under
Figure 3. PrP
TSE-associated seeding activity in muscles from
CWD-infected WTD. Western blot detection of Proteinase K-resistant
prion protein (PrPres) after PMCA. For PMCA normal hamster brain
homogenate was seeded with 10 ml of a 10% (w/v) CWD brain
homogenate from an infected WTD (A), or with PrP
TSE-extract from M.
semimembranosus/tendinosus of a CWD-infected WTD (Fa-WTD 1, B). In
(C) PMCA was seeded with M. semimembranosus/tendinosus from Fa-
WTD 2 that had been tested positive for PrP
TSE in brain tissue while no
PrP
TSE could be detected by Western blotting in muscle extracts of this
animal (the negative result with this muscle is shown in figure 2, lane 8).
(D) Unseeded control in which PMCA was performed with normal
hamster brain homogenate only. Lanes 1–7 represent Western blot
findings after 1, 2, 3, 4, 5, 6 and 7 rounds of PMCA. Lane 8, Proteinase K-
digested brain homogenate from a hamster in the clinical stage of
scrapie representing 1610
27 g of hamster brain tissue (loaded as an
internal blotting control). M: molecular mass marker. Anti-PrP mono-
clonal antibody 3F4 was used as primary antibody for the detection of
PrPres.
doi:10.1371/journal.pone.0018345.g003
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harvested at necropsy using separate sets of instruments and
separate table coverings. Western blot analyses for the presence or
absence of detectable PrP
TSE in brain tissue and/or lymph nodes
from the donor animals of this study were conducted, in the
context of CWD surveillance, by the responsible authorities in
Canada or the USA. Except for the donor animal of negative
control muscle (dissected from unaffected WTD without detect-
able PrP
TSE in lymph nodes or brain [Fa-WTD 10]) all animals we
examined for PrP
TSE in skeletal muscles had been officially
confirmed positive for CWD based on the detection of PrP
TSE in
lymph nodes or brain (table 1).
For these cervids, however, no clinical signs of CWD had been
recognized. Several different symptoms may clinically indicate
CWD: Behavioural changes (e. g. reduced interaction with or
separation from other animals of the herd, stereotypy, listlessness/
apathy, depression, aggressive behaviour, conspicuous excitabili-
ty), neurological signs (e. g. subtle tremor of the head, ataxia, signs
of paralysis, impairment of proprioception, swallowing difficulties,
atypical movements of the tongue, teeth grinding), as well as
polydipsia, polyuria, excessive salivation, pneumonia, weight loss
and wasting. None of these symptoms was reported for the hunted
game WTD from Wisconsin (USA). Clinically inconspicuous
captive donor animals of our study were culled on a farm in
Saskatchewan (Canada) after all WTD showing behaviour or
symptoms possibly indicative of CWD (as observed by staff of the
Canadian Food Inspection Agency) had been removed from the
herd.
The cervid muscle specimens examined in this study were
provided by the Saskatoon District Office of the Canadian Food
Inspection Agency (Canada) or the Wisconsin Department of
Natural Resources (USA), while normal hamster brain tissue was
prepared from Syrian hamsters kept at the Robert Koch-Institut in
Berlin (Germany). Reference brain tissue from WTD in the
clinical stage of CWD was provided by Juergen Richt (Department
of Diagnostic Medicine/Pathobiology, College of Veterinary
Medicine, Kansas State University, Manhatten, KS, USA).
Extraction of PrP
TSE from muscle samples
For the extraction of PrP
TSE from muscle samples we used a
previously published protocol [31] with modifications: 100 mg
specimens of muscle tissue were cut into small pieces and washed
twice in TBS (Tris-buffered saline [10 mM Tris-HCl, 133 mM
NaCl, pH 7.4]). Samples were incubated in 900 ml of TBS
containing 2 mM CaCl2 and 0.25% (w/v) collagenase A (Roche)
for 3.5 h at 37uC on a shaking device. For positive controls, muscle
Figure 4. Intramuscular location of PrP
TSE in skeletal muscle tissue of CWD-infected WTD. (A) Tissue-blot from M. glutaeobiceps of CWD-
infected WTD (FR-WTD 2). Distinct granular endoneural PrP
TSE accumulation in muscle-associated nerve fascicles visualised by immunolabelling with
the monoclonal anti-PrP antibody P4. No PrP
TSE accumulation could be detected in muscle fibres. (B) H&E stained slice from the same tissue block as
in (A) showing nerves embedded in the muscle tissue. (C) Control tissue-blot of M. glutaeobiceps from uninfected WTD (Fa-WTD 10). (D) H&E stained
slice from the same tissue block as in (C). Arrows indicate muscle-associated nerve fascicles in A–D. Bars=2 mm.
doi:10.1371/journal.pone.0018345.g004
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TSE by adding
defined amounts of brain homogenate from WTD in the clinical
stage of CWD. After collagenase A digestion samples were
sonicated (Kontes, micro-ultrasonic cell disrupter) and centrifuged
at 5.000 rpm (using a TLA-55 rotor) for 3 minutes at 4uC. The
supernatant was transferred into a new tube. The pellet was
vortexed in 0.5 ml TBS and again centrifuged at 5.000 rpm (TLA-
55 rotor) for 3 min at 4uC. The supernatant from the second
5.000 rpm centrifugation was combined with that of the first
5.000 rpm centrifugation and centrifuged for 40 min at
20.000 rpm (TLA-55 rotor) at 4uC. The supernatant was
discarded and the pellet resuspended in 1 ml of 1% (w/v) sarcosyl
(N-Lauroylsarcosine-sodium-salt [Serva])/TBS by sonication.
After centrifugation at 45.000 rpm (TLA-55 rotor) for 2.5 h at
4uC the supernatant was discarded and the pellet resuspended,
again by sonication, in 1 ml 0.1% (w/v) sarcosyl, 10% (w/v)
NaCl/TBS. 2.5 mg Proteinase K (Boehringer) were added and
samples were centrifuged for 2.5 h at 45.000 rpm (TLA-55 rotor)
at 4uC. The supernatant was discarded and the pellet was
harvested for Western blot detection of PrP
TSE.
Western blot detection of PrP
TSE
For Western blotting final pellets harvested after extraction of
PrP
TSE from muscle samples were resuspended in 10 ml of distilled
water, mixed with an equal volume of 26electrophoresis sample
buffer (4% [w/v] SDS, 10% [v/v] 2-mercaptoethanol in 120 mM
Tris-HCl, pH 6.8, containing 20% [w/v] glycerol and 0.05% [w/
v] bromphenol blue) and heated to 100uC for 5 min. CWD brain
homogenate was digested with 50 mg PK/ml at 37uC for 40 min.
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and West-
ern blot analyses were performed, in principle, as described
elsewhere [10] with specific adjustments for the detection of
CWD-associated PrP
TSE: After running SDS-PAGEs using 15%
SDS-polyacrylamide gels, proteins were transferred to polyviny-
lidene difluoride membranes (Immobilon; Millipore) using a semi-
dry blot system (Biometra). Membranes were incubated in TBS
containing 0.05% Tween (TBST) for 1 h at 20uC. Blots were
incubated overnight at 4uC in primary antibody solution
(monoclonal anti-PrP antibody ICSM18 [D-Gen], diluted 1 :
10.000 in TBST). After washing three times for 10 min with
TBST blots were incubated in secondary antibody solution
(alkaline-phosphatase-conjugated goat anti-mouse IgG [DAKO]
diluted 1 : 10.000 in TBST) for 90 min at 20uC. After washing
three times for 10 min membranes were incubated twice for 5 min
in buffer solution (100 mM Tris, 100 mM NaCl, pH 9.5) and
subsequently developed with CDP-Star solution (Tropix; Applied
Biosystems) for 5 min, according to the manufacturer’s instruc-
tions. PrP signals were visualised using Amersham Hyperfilm ECL
(GE Healthcare).
Postfixed frozen tissue blotting
Ten-micron frozen sections of muscle tissue (M. glutaeobiceps)
were cut on a Reichart-Jung cryomicrotome, mounted on
nitrocellulose membranes (0.45-mm pore size; Bio-Rad) and fixed
for 1 hour in 4% para-formaldehyde in PBS (phosphate buffered
saline [4.3 mM Na2HPO4, 1.4 mM KH2PO4, 137 mM NaCl,
2.7 mM KCl, pH 7.4]). Protease digestion was performed with
100 mg/ml trypsin (5000 USP-U/mg, salt free; ROTH) in
100 mM Tris-HCl (pH 8.3) at 37uC for 45 minutes. Proteins
were denatured by incubation in 4 M guanidine isothiocyanate for
30 minutes. Thereafter, the membranes were further processed
according to the paraffin-embedded tissue (PET) blot protocol
described elsewhere [32,33]. Primary monoclonal antibody P4 (R-
Biopharm), diluted 1:5000 in TBST, was used for PrP-detection.
Tissue sections from the same block were placed on glass slides and
stained with haematoxylin and eosin (H&E) for anatomical
orientation.
Protein Misfolding Cyclic Amplification (PMCA)
PMCA was carried out according to a previously published
protocol [34] with modifications: Brains taken from normal Syrian
hamsters were homogenized in conversion buffer (PBS [8 mM
Na2HPO4, 1.5 mM KH2PO4, 137 mM NaCl, 2.7 mM KCl,
pH 7.4] containing complete protease inhibitor cocktail [Boeh-
ringer-Ingelheim], 4 mM EDTA and 1% Triton-X-100). The
normal hamster brain homogenate was adjusted to a concentra-
tion of 1 g brain tissue per 10 ml (i. e. to 10% [w/v]), and used as
substrate for PMCA. PrP
TSE-muscle extracts from CWD-infected
cervids were prepared according to the protocol described above
with modifications: 100 mg of specimens of skeletal muscle were
cut into small pieces and washed twice in 16TBS. Samples were
incubated in 900 ml1 6TBS containing 2 mM CaCl2 and 0.25%
(w/v) collagenase A (Roche) for 3.5 h at 37uC on a shaking device.
After incubation at 80uC for 10 min samples were further
homogenized by sonication. Samples were centrifuged at
5.000 rpm (using a TLA-55 rotor) for 3 minutes at 4uC. The
supernatant was transferred into a new tube. The pellet was
vortexed in 0.5 ml TBS and again centrifuged at 5.000 rpm (TLA-
55 rotor) for 3 min at 4uC. The supernatant from the second
5.000 rpm centrifugation was combined with that of the first
5.000 rpm centrifugation. The combined supernatants were
centrifuged for 2.5 h at 45.000 rpm and 4uC using a TLA-55
rotor. Resulting supernatants were discarded and pellets were
resuspended in 100 ml conversion buffer. For the seeding of
PMCA with PrP
TSE extracts from muscle tissue 20 ml aliquots of
resuspended pellets were mixed with 130 ml of 10% (w/v) normal
hamster brain homogenate. 140 ml of 10% (w/v) normal hamster
brain homogenate were used as substrate when PMCA was
seeded, as a positive control, with 10 ml of a 10% (w/v) CWD
brain homogenate (that had been similarly prepared as described
above for normal hamster brain homogenate) from a WTD in the
clinical stage of disease. As a negative control unseeded PMCA
was performed only with normal hamster brain homogenate. In
order to prevent cross-contamination of samples during PMCA all
pipetting steps were performed with plugged single-use pipette tips,
and gloves were changed each time before handling a new sample.
PMCA was performed in 0.5 ml Eppendorf safe lock tubes that
had been subjected to steam sterilization at 121uC and 3 bar for
20 min prior to use and were sealed with parafilm and paraffin
wax before PMCA processing. PMCA was carried out using an
automatic sonication apparatus (Sonicator S-4000 from Misonix,
New York, USA). After each round of PMCA 75 ml aliquots of
PMCA batches were transferred into 75 ml of fresh normal
hamster brain homogenate. One round of PMCA consisted of 24
alternating cycles of sonication (for 40 sec every 60 min) and
incubation of samples at 37uC between sonications. PMCA-
batches obtained after 1, 2, 3, 4, 5, 6 and 7 rounds of PMCA were
exposed to Proteinase K at a concentration of 150 mg PK/ml and
incubated for 1 h at 55uC. After centrifugation for 1 min at
13.000 g and room temperature, 30 ml aliquots of PK-digested
PMCA-samples were mixed with 30 mlo f2 6 electrophoresis
sample buffer, each, and heated for 10 min at 100uC. Subse-
quently, 10 ml aliquots of these samples were subjected to SDS-
PAGE and Western blotting. PK-resistant prion protein (PrPres) in
PMCA products was labelled with the monoclonal anti-PrP
antibody 3F4 [10] which does not recognize CWD-associated
PrP
TSE.
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